Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and ...

APX-3330 is under clinical development by Opus Genetics and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase II drugs for Non-Proliferative ...

The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This ...

The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel ...